Summit Trail Advisors LLC Has $302,000 Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Summit Trail Advisors LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,285 shares of the biopharmaceutical company’s stock after buying an additional 151 shares during the quarter. Summit Trail Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $302,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of ALNY. Savant Capital LLC lifted its position in Alnylam Pharmaceuticals by 57.6% during the 4th quarter. Savant Capital LLC now owns 11,738 shares of the biopharmaceutical company’s stock worth $2,762,000 after acquiring an additional 4,291 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Alnylam Pharmaceuticals by 8.0% in the fourth quarter. Empowered Funds LLC now owns 7,630 shares of the biopharmaceutical company’s stock worth $1,795,000 after purchasing an additional 566 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $41,529,000. Finally, Bleakley Financial Group LLC grew its holdings in Alnylam Pharmaceuticals by 16.9% in the 4th quarter. Bleakley Financial Group LLC now owns 2,590 shares of the biopharmaceutical company’s stock valued at $610,000 after buying an additional 375 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on ALNY shares. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Finally, TD Cowen boosted their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Insider Buying and Selling

In other news, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,964 shares of company stock worth $20,622,925 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $265.96 on Thursday. The business’s fifty day moving average is $253.77 and its two-hundred day moving average is $262.99. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market cap of $34.30 billion, a P/E ratio of -101.51 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.